Advertise here
Advertise here

Novo Nordisk’s weekly insulin rejected by FDA

The Food and Drug Administration rejected Novo Nordisk’s weekly insulin for diabetes treatment due to concerns about manufacturing and use in type 1 diabetes patients. The company does not expect to fulfill the FDA’s requests this year. The FDA previously convened a panel of advisers who voted against approval for type 1 patients, citing concerns about potential risks of low blood sugar. Novo Nordisk had submitted the drug application for both type 1 and type 2 patients. The decision marks a rare setback for the pharmaceutical giant.

Source link

Advertise here
error: Content is protected !!